Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.80 |
| ▸ | TTR | P02766 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | CASP1 | P29466 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | CASP7 | P55210 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3284626 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10TTRMAPT | |
| SCHEMBL3278525 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10TTRMAPT | |
| SCHEMBL6030712 | 0.88 | KDM4E (0.80) | KDM4EALDH1A1HSD17B10TTRMAPT | |
| SCHEMBL1720125 | 0.88 | KDM4E (0.80) | KDM4EALDH1A1HSD17B10TTRMAPT | |
| SCHEMBL1718125 | 0.85 | MAPT (0.80) | KDM4EALDH1A1HSD17B10MAPTCASP1 | |
| SCHEMBL1718174 | 0.85 | ALDH1A1 (0.83) | KDM4EALDH1A1HSD17B10TTRMAPT | |
| SCHEMBL1718303 | 0.84 | HPGD (0.82) | KDM4EALDH1A1HSD17B10MAPTCASP1 | |
| SCHEMBL4201038 | 0.83 | HPGD (0.81) | KDM4EALDH1A1HSD17B10MAPTCASP1 | |
| SCHEMBL1719057 | 0.83 | HPGD (0.81) | KDM4EALDH1A1HSD17B10MAPTCASP1 | |
| SCHEMBL1718676 | 0.83 | TTR (1.00) | KDM4EALDH1A1HSD17B10TTRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506196-B1 | PYRAZOLOPYRIMIDINES AS SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2012-01-18 | — | — | EP | disclosed |
| EP-1506196-A4 | PYRAZOLOPYRIMIDINES | ICAGEN INC (US) | 2008-01-02 | — | — | EP | disclosed |
| US-7098335-B2 | Pyrazolopyrimidine compositions | ICAGEN, INC. (US) | 2006-08-29 | — | — | US | disclosed |
| US-20050215569-A1 | Pyrazolopyrimidines | ICAGEN, INC. (US) | 2005-09-29 | — | — | US | disclosed |
| EP-1506196-A2 | PYRAZOLOPYRIMIDINES | Icagen, Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
| US-6833371-B2 | Contacting cell with a sodium channel-inhibiting amount of a compound comprising a pyrazolopyrimidine moiety for decreasing ion flow through a voltage-dependent sodium channel in a cell | ICAGEN, INC. | 2004-12-21 | — | — | US | disclosed |
| US-20030176450-A1 | Pyrazolopyrimidines | ICAGEN, INC. (US) | 2003-09-18 | — | — | US | disclosed |
| WO-2003037900-A2 | PYRAZOLOPYRIMIDINES | ICAGEN, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215569-A1 | Pyrazolopyrimidines | SCN3A, TRPV3, P2RX3 | KDM4E 2962/4885ALDH1A1 2830/4885HSD17B10 3989/4885 |
| US-20030176450-A1 | Pyrazolopyrimidines | SCN3A, TRPV3, P2RX3 | KDM4E 2962/4885ALDH1A1 2830/4885HSD17B10 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.